Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple versus dual antimalarial combination therapy for uncomplicated falciparum malaria
PACTR202601913078109Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3 trial of artemether, lumefantrine, amodiaquine and artesunate in malaria and Malaria (3 arms), sponsored by University of Oxford. Primary endpoint: 28-day PCR-corrected adequate clinical and parasitological response. Started Mar 2024; status: recruiting.
02
Drugs
artemetherlumefantrineamodiaquineartesunate
03
Conditions
malariaMalaria
Beyond the preview
Go deeper on PACTR202601913078109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202601913078109.